Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection
DOI:
https://doi.org/10.20882/adicciones.1551Keywords:
HCV, central nervous system, drug interactions, pangenotypic direct-acting antivirals.Abstract
Our objective was to determine potential drug interactions (DI) between pangenotypic direct-acting antivirals (pDAA) and concomitant central nervous system (CNS) medication in patients with chronic hepatitis C virus (HCV). Transversal design. Patients aged ≥ 18 years on treatment with pDAA during 2017 were included. The variables collected were comorbidity, concomitant CNS medication and potential DI. The pDAA analyzed were a) Sofosbuvir/Velpatasvir (SOF/VEL), b) Glecaprevir/Pibrentasvir (GLE/PIB) and c) Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX). Descriptive statistical analysis. We recruited 1,170 patients (mean age 60.1 years, 56.4% male). Mean concomitant drug use was 3.2 per patient/year. The percentages of potential / possible DI between the DAAs and the concomitant drugs on the CNS were: 2.7% contraindications, 11.3% significant and 4.2% weak. By pDAA, the percentages were: SOF/VEL (2.7%; 0.0%; 4.4%), GLE/GDP (2.7%; 26.5%; 1.6%) SOF/VEL/VOX (2.7%; 6.8%; 4.4%), respectively. Concomitant CNS medication was used in one third of HCV patients. It is important to select a pDAA with a low rate of potential DI to simplify treatment. SOF/VEL is a good alternative compared with the other pDAA studied, mainly due to the concomitant use of antipsychotics and analgesics.References
Ahmed, A., Lutchman, G. A. & Kwo, P. Y. (2017). Drug-drug interactions in hepatitis C virus treatment: Do they really matter? Clinical Liver Disease, 10, 111-115. doi:10.1002/cld.668.
Benet, L. Z., Bowman, C. M., Koleske, M. L., Rinaldi, C. L. & Sodhi, J. K. (2019). Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. Journal of Pharmacokinetics and Pharmacodynamics, 46, 155-163. doi:10.1007/s10928-019-09626-7.
Calleja, J. L., Macias, J., Forns, X., Garcia, F., Berenguer, M., Garcia Deltoro, M.,… Pineda, J. A. (2018). Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH). Gastroenterologia y Hepatologia, 41, 597-608. doi:10.1016/j.gastrohep.2018.07.010.
Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Dseases, 40, 373-383. doi:10.1016/0021-9681(87)90171-8.
European Association for the Study of the Liver (2018). EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 69, 461-511. doi:10.1016/j.jhep.2018.03.026.
Garrison, K. L., German, P., Mogalian, E. & Mathias, A. (2018). The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 46, 1212-1225. doi:10.1124/dmd.117.079038.
Keast, S. L., Holderread, B., Cothran, T. & Skrepnek, G. H. (2019). Hepatitis C direct-acting antiviral treatment selection, treatment failure, and use of drug-drug interactions in a state medicaid program. Journal of Managed Care and Specialty Pharmacy, 25, 1261-1267. doi:10.18553/jmcp.2019.25.11.1261.
Kondili, L. A., Gaeta, G. B., Leluzzi, D., Zignego, A. L., Monti, M., Gori, A.,… Puoti, M. (2017). Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PloS One, 12, e0172159. doi:10.1371/journal.pone.0172159.
Langness, J. A., Nguyen, M., Wieland, A., Everson, G. T. & Kiser, J. J. (2017). Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World Journal of Gastroenterology, 23, 1618-1626. doi:10.3748/wjg.v23.i9.1618.
Lauffenburger, J. C., Mayer, C. L., Hawke, R. L., Brouwer, K. L., Fried, M. W. & Farley, J. F. (2014). Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: High utilization of drugs with interaction potential. European Journal of Gastroenterology and Hepatology, 26, 1073-1082. doi:10.1097/MEG.0000000000000152.
Laursen, T. L., Sandahl, T. D., Kazankov, K., George, J. & Grønbæk, H. (2020). Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology, 26, 2931-2947. doi:10.3748/wjg.v26.i22.2931.
Maasoumy, B., Port, K., Calle Serrano, B., Markova, A. A., Sollik, L., Manns, M. P.,… Wedemeyer, H. (2013). The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 38, 1365-1372. doi:10.1111/apt.12523.
Morozov, V. A. & Lagaye, S. (2018). Hepatitis C virus: Morphogenesis, infection and therapy. World Journal of Hepatology, 10, 186–212. doi:10.4254/wjh.v10.i2.186.
Paolucci, S., Novazzi, F., Piralla, A., Maserati, R., Gulminetti, R., Novati, S.,… Baldanti, F. (2019). Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations. Infection and Drug Resistance, 12, 1975–1984. doi:10.2147/IDR.S205282.
Roncero, C., Villegas, J. L., Martínez-Rebollar, M. & Buti, M. (2018). The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Review of Clinical Pharmacology, 11, 999-1030. doi:10.1080/17512433.2018.1519392.
Sicras Mainar, A., Navarro Artieda, R., Hernández, I. & Morillo, R. (2019). Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. Gastroenterologia y Hepatologia, 42, 465-475. doi:10.1016/j. gastrohep.2019.03.014.
Sicras-Mainar, A., Enríquez, J.L., Hernández, I., Sicras-Navarro, A., Aymerich, T. & Leon, M. (2019). Validation and representativeness of the Spanish BIG-PAC database: Integrated computerized medical records for research into epidemiology, medicines and health resource use (real word evidence). Value in Health, 22 (Suppl. 3), S734. doi:10.1016/j.jval.2019.09.1764.
Talavera Pons, S., Boyer, A., Lamblin, G., Chennell, P., Châtenet, F. T., Nicolas, C.,… Abergel, A. (2017). Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. British Journal of Clinical Pharmacology, 83, 269-293. doi:10.1111/bcp.13095.
The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD): World Health Organization (2019). Retrieved at http://www.who.int-/classifications /atcddd/en/.
University of Liverpool HIV and Hepatitis Pharmacology Group Drug Interaction Charts (2020). Retrieved at http://www.hep-druginteractions.org/Interactions.aspx.
World Health Organization (2018). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Retrieved at http://www.who.int-/hepatitis/publications/hepatitis-c-guidelines-2018/en/.
Zoratti, M. J., Siddiqua, A., Morassut, R. E., Zeraatkar, D., Chou, R., van Holten, J.,… Druyts, E. (2020). Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. EClinicalMedicine, 18, 100237. doi:10.1016/j.eclinm.2019.12.007.
